DelveInsight’s, “Metastatic Hepatocellular Carcinoma Pipeline Insight 2024” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Metastatic Hepatocellular Carcinoma pipeline landscape. It covers the Metastatic Hepatocellular Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Metastatic Hepatocellular Carcinoma Pipeline. Dive into DelveInsight’s comprehensive report today! @ Metastatic Hepatocellular Carcinoma Pipeline Outlook

Key Takeaways from the Metastatic Hepatocellular Carcinoma Pipeline Report

• July 2024:- Hoffmann-La Roche– A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma.
• July 2024:- Asan Medical Center- Multicenter Phase 2 Trial of Lenvatinib in Patients With Unresectable or Metastatic Hepatocellular Carcinoma After Progression on First-line Atezolizumab Plus Bevacizumab.
• July 2024:- AbbVie– A Phase 2/3, Randomized Study to Evaluate the Dose Optimization, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab in Subjects With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic Treatment.
• DelveInsight’s Metastatic Hepatocellular Carcinoma Pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline therapies for Metastatic Hepatocellular Carcinoma treatment.
• The leading Metastatic Hepatocellular Carcinoma Companies such as CStone Pharmaceuticals, Coherus BioSciences, Tvardi Therapeutics, Sapience Therapeutics, Inc., Eureka Therapeutics Inc., Krystal Biotech, Inc., Replimune Inc., Beijing Syngentech Co., Ltd., Boehringer Ingelheim, AbbVie, Chugai Pharmaceutical, GenVivo, Inc., Suzhou Kintor Pharmaceutical Inc, Shanghai Henlius Biotech, and others.
• Promising Metastatic Hepatocellular Carcinoma Therapies such as Atezolizumab, Bevacizumab, Tiragolumab, HLX53 (1000mg), Lenvatinib, and others.

Stay ahead with the most recent pipeline outlook for Metastatic Hepatocellular Carcinoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Metastatic Hepatocellular Carcinoma Treatment

Metastatic Hepatocellular Carcinoma Emerging Drugs Profile

• CS1003: CStone Pharmaceuticals

CS1003 or Nofazinlimab is a humanized recombinant IgG4 monoclonal antibody targeting human programmed cell death protein 1 (PD-1) being developed in solid tumors. Nofazinlimab shows comparable high binding affinities to the PD-1 of humans, cynomolgus monkey, and mouse, and can block the interaction of PD-1 with its ligands PD-L1 and PD-L2. The U.S. FDA has granted nofazinlimab Orphan Drug Designation (ODD) in July 2020 for the treatment of patients with HCC. CStone formed a strategic collaboration agreement with EQRx, under which EQRx licensed the exclusive rights to two immuno-oncology assets, sugemalimab and nofazinlimab, for development and commercialization outside of Greater China. CStone retains rights to nofazinlimab in Greater China, where it can continue to pursue development as a monotherapy or as part of its combination strategy for this drug. Currently, the drug is in Phase III stage of its development for the treatment of hepatocellular carcinoma.

• Casdozokitug: Coherus BioSciences

Casdozokitug is a human anti-IL-27 antibody designed to inhibit the activity of this immune regulatory cytokine. The company is focused on developing casdozokitug in particular tumor types where IL-27 secreted from macrophages appears to play an important role in the immunosuppressive tumor microenvironment and may contribute to resistance to treatment with immune checkpoint inhibitors. Preclinical studies have shown that treatment with casdozokitug blocks the immunosuppressive biologic effects of IL-27, resulting in immune cell activation in combination with other cancer therapies including anti-PD-1 therapy, as well as anti-tumor effects. Casdozokitug has been granted Orphan Drug designation and Fast Track designation for the treatment of refractory hepatocellular carcinoma from the FDA. It is the first IL-27 antibody to enter the clinic. Currently, the drug is in Phase II stage of its development for the treatment of hepatocellular carcinoma.

• TTI-101: Tvardi Therapeutics

TTI-101 is an orally bioavailable, small-molecule inhibitor of signal transducer and activator of transcription 3 (STAT3), a transcription factor whose upregulation and activation governs many hallmarks of cancer, inflammation, and fibrosis. Preclinically, TTI-101 has demonstrated an excellent pharmacokinetic profile, potency in inhibiting STAT3 activation, and efficacy in inhibiting tumor growth in xenograft and syngeneic tumor models. In its first-in-man Phase 1 trial conducted in patients with relapsed/refractory tumors, TTI-101 monotherapy was well-tolerated and had clinical activity across a broad range of tumors including multiple durable radiographic objective responses. Currently, the drug is in Phase II stage of its development for the treatment of hepatocellular carcinoma.

• ST316: Sapience Therapeutics, Inc.

ST316, a first-in-class antagonist of the interaction between ß-catenin and its co-activator BCL9, is being evaluated in the Phase I portion of a Phase I-II clinical study in patients with selected advanced unresectable and metastatic solid tumors. ST316-101 is an open-label, two-part study. The Phase I dose-escalation portion of the study is designed to determine the safety, tolerability, PK, and PD of ST316 in patients with selected advanced solid tumors likely to harbor abnormalities of the Wnt/ß-catenin signaling pathway. The Phase II dose-expansion portion aims to continue to assess the safety of ST316 as well as proof of concept in four specific tumor types known to harbor abnormalities of the Wnt/ß-catenin signaling pathway. Currently, the drug is in Phase I/II stage of its development for the treatment of hepatocellular carcinoma.

Explore groundbreaking therapies and clinical trials in the Metastatic Hepatocellular Carcinoma Pipeline. Access DelveInsight’s detailed report now! @ New Metastatic Hepatocellular Carcinoma Drugs

Metastatic Hepatocellular Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Metastatic Hepatocellular Carcinoma Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Unveil the future of Metastatic Hepatocellular Carcinoma treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Metastatic Hepatocellular Carcinoma Market Drivers and Barriers

Scope of the Metastatic Hepatocellular Carcinoma Pipeline Report

• Coverage- Global
• Metastatic Hepatocellular Carcinoma Companies- CStone Pharmaceuticals, Coherus BioSciences, Tvardi Therapeutics, Sapience Therapeutics, Inc., Eureka Therapeutics Inc., Krystal Biotech, Inc., Replimune Inc., Beijing Syngentech Co., Ltd., Boehringer Ingelheim, AbbVie, Chugai Pharmaceutical, GenVivo, Inc., Suzhou Kintor Pharmaceutical Inc, Shanghai Henlius Biotech, and others.
• Metastatic Hepatocellular Carcinoma Therapies- Atezolizumab, Bevacizumab, Tiragolumab, HLX53 (1000mg), Lenvatinib, and others.
• Metastatic Hepatocellular Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Metastatic Hepatocellular Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Metastatic Hepatocellular Carcinoma therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Metastatic Hepatocellular Carcinoma Companies, Key Products and Unmet Needs

Table of Content

1. Introduction
2. Executive Summary
3. Metastatic Hepatocellular Carcinoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Metastatic Hepatocellular Carcinoma– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. CS1003: CStone Pharmaceuticals
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Casdozokitug: Coherus BioSciences
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. ST316: Sapience Therapeutics, Inc.
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Metastatic Hepatocellular Carcinoma Key Companies
21. Metastatic Hepatocellular Carcinoma Key Products
22. Metastatic Hepatocellular Carcinoma- Unmet Needs
23. Metastatic Hepatocellular Carcinoma- Market Drivers and Barriers
24. Metastatic Hepatocellular Carcinoma- Future Perspectives and Conclusion
25. Metastatic Hepatocellular Carcinoma Analyst Views
26. Metastatic Hepatocellular Carcinoma Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/